FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE
CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY

SKIN CLEARANCE SHOULD
STAND THE TEST OF TIME*

*Test of time refers to 48 weeks.

Based on the results of an analysis of the 101 global sites from VOYAGE 1 (including North American sites [ie, US and Canada]); the analysis of the North American sites is provided HERE »

3 YEAR  DATA AVAILABLE

FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY

SKIN CLEARANCE SHOULD STAND THE TEST OF TIME*

*Test of time refers to 48 weeks.

Based on the results of an analysis of the 101 global sites from VOYAGE 1 (including North American sites [ie, US and Canada]); the analysis of the North American sites is provided HERE »

In VOYAGE 1, 837 patients were randomized to placebo (n=174), TREMFYA® 100 mg every 8 weeks (q8w) after Weeks 0 and 4 (n=329), or Humira® (adalimumab) 80 mg at Week 0, 40 mg at Week 1, and 40 mg every 2 weeks thereafter (n=334). Eligible patients (≥18 years of age) had moderate to severe plaque psoriasis (ie, Investigator's Global Assessment [IGA] score ≥3, Psoriasis Area and Severity Index [PASI] score ≥12, body surface area [BSA] involvement ≥10%) for at least 6 months and were candidates for systemic therapy or phototherapy. The study comprised a placebo-controlled period (Weeks 0 to 16) after which patients taking placebo crossed over to receive TREMFYA® at Weeks 16 and 20 and q8w thereafter through Week 48, and an active-comparator–controlled period when TREMFYA® was compared with Humira® from Week 0 through Week 48.¹

Please see complete Study Design.

TREMFYA® (guselkumab) is a registered trademark of Janssen Biotech, Inc.

Humira® (adalimumab) is a registered trademark of AbbVie Inc.

References: 1. TREMFYA® (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 2. Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417.

PATIENT SUPPORT for TREMFYA®

Access, affordability, and treatment support available through Janssen CarePath.

Learn more

Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

Adverse Reactions
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-57257v1